Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: an AI model using wearable single-lead ECG accurately detected elevated left atrial pressure, a meta-analysis of randomized trials showed atrial fibrillation screening reduces thromboembolic events, and a mechanistic study uncovered a TRIM21–MAPK6 pathway by which disturbed shear stress accelerates atherosclerosis. Together, these advance remote hemodynamic monitoring, clarify the value of AF screening, and identify a novel anti-atherosclerotic
Summary
Three impactful cardiology studies stood out today: an AI model using wearable single-lead ECG accurately detected elevated left atrial pressure, a meta-analysis of randomized trials showed atrial fibrillation screening reduces thromboembolic events, and a mechanistic study uncovered a TRIM21–MAPK6 pathway by which disturbed shear stress accelerates atherosclerosis. Together, these advance remote hemodynamic monitoring, clarify the value of AF screening, and identify a novel anti-atherosclerotic target.
Research Themes
- AI-enabled noninvasive hemodynamic monitoring
- Population-level impact of atrial fibrillation screening
- Mechanotransduction pathways driving atherosclerosis
Selected Articles
1. Artificial intelligence for hemodynamic monitoring with a wearable electrocardiogram monitor.
A deep neural network trained on single-lead ECG identified elevated left atrial pressure with AUC 0.80 (internal), 0.76 (external), and 0.875 in a prospective patch-ECG cohort near right heart catheterization. This demonstrates feasibility of ambulatory, noninvasive hemodynamic monitoring using wearable ECG data.
Impact: Noninvasive, scalable detection of elevated left atrial pressure could transform heart failure surveillance and decompensation prevention. The model shows robust performance across internal, external, and prospective datasets.
Clinical Implications: This approach could enable remote detection of hemodynamic congestion, guide diuretic titration, and trigger earlier interventions in heart failure management using widely available wearable ECG patches.
Key Findings
- Internal validation AUC for elevated left atrial pressure detection was 0.80; external validation AUC was 0.76.
- Prospective patch-ECG cohort near right heart catheterization achieved AUC 0.875.
- Model leverages single-lead wearable ECG, supporting ambulatory hemodynamic monitoring.
Methodological Strengths
- Multi-cohort evaluation (internal, external, and prospective patch-ECG validation)
- Objective reference with right heart catheterization in the prospective subset
Limitations
- Prospective cohort size not specified in the abstract and likely small
- Model interpretability and generalizability to home settings and varied comorbidities require further study
Future Directions: Larger prospective, multi-center studies with longitudinal monitoring to test clinical utility for decompensation prediction and to assess workflow integration and outcome impact.
BACKGROUND: The ability to non-invasively measure left atrial pressure would facilitate the identification of patients at risk of pulmonary congestion and guide proactive heart failure care. Wearable cardiac monitors, which record single-lead electrocardiogram data, provide information that can be leveraged to infer left atrial pressures. METHODS: We developed a deep neural network using single-lead electrocardiogram data to determine when the left atrial pressure is elevated. The model was developed and internally evaluated using a cohort of 6739 samples from the Massachusetts General Hospital (MGH) and externally validated on a cohort of 4620 samples from a second institution. We then evaluated model on patch-monitor electrocardiographic data on a small prospective cohort. RESULTS: The model achieves an area under the receiver operating characteristic curve of 0.80 for detecting elevated left atrial pressures on an internal holdout dataset from MGH and 0.76 on an external validation set from a second institution. A further prospective dataset was obtained using single-lead electrocardiogram data with a patch-monitor from patients who underwent right heart catheterization at MGH. Evaluation of the model on this dataset yielded an area under the receiver operating characteristic curve of 0.875 for identifying elevated left atrial pressures for electrocardiogram signals acquired close to the time of the right heart catheterization procedure. CONCLUSIONS: These results demonstrate the utility and the potential of ambulatory cardiac hemodynamic monitoring with electrocardiogram patch-monitors. Heart failure is a common disorder that is challenging to manage. Appearance of symptoms can be subtle and dangerous and there are few tools for clinicians to estimate when a patient is likely to experience an episode of heart failure. Current methods to detect elevated pressure in the heart (one sign of oncoming failure) are invasive and can only be performed in an inpatient setting. A non-invasive, quick method for detecting higher heart pressure would be helpful for identifying worsening heart failure in the home environment. For this reason, we developed a computer method to detect elevated pressures inside the heart using a non-invasive signal from a wearable patch monitor device, the electrocardiogram (ECG, or EKG). Our results show our method provides a reliable, non-invasive way to measure heart pressures using data that can be obtained in the outpatient setting.
2. Atrial fibrillation screening and clinical outcomes: a meta-analysis of randomized controlled trials.
Across 6 RCTs (n=74,145), AF screening increased AF detection and anticoagulation initiation and modestly reduced ischemic stroke and thromboembolism without increasing major bleeding or mortality. These findings support targeted AF screening programs.
Impact: This meta-analysis addresses long-standing uncertainty and demonstrates clinical benefit signals of AF screening on thromboembolism, informing guideline harmonization and public health strategies.
Clinical Implications: Implement AF screening in at-risk populations (e.g., older adults) with clear pathways for confirmatory testing and anticoagulation initiation, while monitoring for bleeding and optimizing patient selection.
Key Findings
- AF screening doubled AF detection (RR 2.54) and increased oral anticoagulation initiation (RR 2.19).
- Ischemic stroke and composite thromboembolism were modestly reduced (RR 0.93 for both outcomes).
- No increase in major bleeding, hemorrhagic stroke, or all-cause mortality.
Methodological Strengths
- Random-effects meta-analysis of six randomized controlled trials
- Large aggregate sample size (n=74,145) with clinically relevant endpoints
Limitations
- Heterogeneity in screening modalities, populations, and follow-up across trials
- Modest absolute risk reductions; cost-effectiveness and implementation logistics require evaluation
Future Directions: Head-to-head trials of screening strategies, stratified by age and risk, with health-economic analyses and assessment of downstream care pathways and patient-reported outcomes.
BACKGROUND: Recommendations on atrial fibrillation (AF) screening by various scientific societies are inconsistent due to uncertainty about its benefit. This study aimed to summarize data from randomized controlled trials (RCTs) on the impact of AF screening on thromboembolism, major bleeding, and mortality. METHODS AND RESULTS: We searched PubMed/MEDLINE and Embase to identify studies providing relevant data through 5 September 2024. Risk ratios (RRs) for each reported outcome of interest were pooled through a meta-analysis with random effects models. We included six RCTs reporting data from 74 145 individuals. AF screening was associated with higher AF detection compared with no intervention [RR 2.54, 95% confidence interval (CI): 1.57-4.11, P < 0.001], and more common initiation of oral anticoagulation (RR 2.19, 1.51-3.18, P < 0.001). Incident ischaemic stroke (RR 0.93, 0.87-1.00, P = 0.048) and thromboembolism including ischaemic stroke, transient ischaemic attack, or systemic embolism (0.93, 95% CI: 0.87-0.99, P = 0.026) were less frequent in individuals who underwent AF screening vs. controls. There was no difference for major bleeding, (RR 0.99, 95% CI: 0.93-1.06, P = 0.830), haemorrhagic stroke (RR 0.94, 95% CI: 0.80-1.11, P = 0.497) and all-cause mortality (RR 0.99, 95% CI: 0.95-1.02, P = 0.411). CONCLUSION: AF screening might be beneficial, especially in reducing thromboembolic events.
3. Disturbed shear stress promotes atherosclerosis through TRIM21-regulated MAPK6 degradation and consequent endothelial inflammation.
Disturbed shear stress triggers TRIM21-mediated ubiquitin–proteasome degradation of endothelial MAPK6, amplifying inflammation (via EGR1/CXCL12) and accelerating atherosclerosis; preserving endothelial MAPK6 attenuated plaque progression in vivo. This identifies MAPK6 as a mechano-regulated anti-atherosclerotic node.
Impact: Elucidates a previously unrecognized mechanotransduction pathway linking disturbed flow to endothelial inflammation and plaque growth, nominating MAPK6 stabilization as a therapeutic strategy.
Clinical Implications: While preclinical, targeting TRIM21–MAPK6 signaling or stabilizing MAPK6 could complement lipid-lowering by directly mitigating flow-induced endothelial inflammation in high-risk vascular regions.
Key Findings
- Disturbed shear stress reduced endothelial MAPK6 via TRIM21-dependent ubiquitin–proteasome degradation in vitro and in vivo.
- Endothelium-specific MAPK6 overexpression decreased atherosclerotic plaque progression in ApoE-deficient models.
- MAPK6 modulated endothelial inflammation through the EGR1/CXCL12 axis.
Methodological Strengths
- Integrated multi-omic and mechanistic approaches (RNA-seq, proteomics, co-IP, single-cell analyses)
- In vivo endothelial-specific gain-of-function validating causal relevance
Limitations
- Details on animal model numbers and effect sizes are not provided in the abstract
- Translational relevance to human vascular beds and potential off-target effects require validation
Future Directions: Develop TRIM21–MAPK6 modulators, test MAPK6 stabilization in large-animal models and human tissues, and assess synergy with lipid-lowering and anti-inflammatory therapies.
RATIONALE: Coronary artery plaques often develop in regions subjected to disturbed shear stress (DSS), yet the mechanisms underlying this phenomenon remain poorly understood. Our study aimed to elucidate the unknown role of MAPK6 in shear stress and plaque formation. METHODS: In vitro and in vivo experiments, RNA-seq, CO-IP and proteomic analysis, combined with single-cell RNA-seq datasets were used to reveal the upstream and downstream mechanisms involved. AAV-MAPK6, ApoE RESULTS: Our study revealed a substantial decrease in MAPK6 protein levels in endothelial cells in response to DSS, both in vivo and in vitro, which was contingent on the binding of the ubiquitin ligase TRIM21 to MAPK6. Endothelium-specific MAPK6 overexpression exerts antiatherosclerotic effects in ApoE CONCLUSIONS: Our study illuminates the advantages of MAPK6 in decelerating plaque progression, highlighting the potential of safeguarding MAPK6 as a novel therapeutic strategy against atherosclerosis. KEY POINTS: Disturbed flow activates the ubiquitin‒proteasome degradation pathway of MAPK6 in endothelial cells, which is contingent on the binding of the ubiquitin ligase TRIM21 to MAPK6. Endothelial MAPK6 has an advantageous impact on decelerating plaque progression. MAPK6 regulates endothelial inflammation via the EGR1/CXCL12 axis.